v3.25.2
Condensed Consolidated Statements of Cash Flows - USD ($)
6 Months Ended 12 Months Ended
Jun. 30, 2025
Jun. 30, 2024
Dec. 31, 2024
Dec. 31, 2023
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss     $ (12,537,472) $ 4,464,079
Adjustments to reconcile net loss to net cash used in operating activities:        
Interest income on investments held in Trust Account     (548,676) (5,813,213)
Change in fair value of convertible note     9,105,853
Interest expense     891,624 8,966
Increase in current assets        
Prepaid expenses     71,884 599,440
Increase in current liabilities        
Accounts payable and accrued liabilities     878,609 (28,629)
Due from related party     (36,503)
Due to affiliate     120,000 116,250
Net cash flows used in operating activities     (2,054,680) (653,107)
Cash Flows from Investing Activities:        
Cash withdrawn from Trust Account in connection with redemptions     13,781,323 284,916,127
Net cash provided by (used in) investing activities     13,781,323 284,916,127
CASH FLOWS FROM FINANCING ACTIVITIES        
Proceeds from Recapitalization     1,711,313
Redemption of ordinary shares     (13,781,323) (284,916,127)
Proceeds from Sponsor note     343,367 155,848
Net cash flows provided by financing activities     (11,726,643) (284,760,279)
NET CHANGE IN CASH     (497,259)
CASH, BEGINNING OF THE PERIOD 497,259
CASH, END OF THE PERIOD    
Supplemental disclosure of noncash activities:        
Deferred underwriting commissions payable charged to additional paid in capital     (10,812,500)
Remeasurement of Class A ordinary shares to redemption value     548,676 5,813,213
Sponsor shares contributed for no redemption of shares     784,302 118,298
Conversion of Class B shares to Class A     719
Aspire Biopharma Inc [Member]        
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss     (1,309,872) (359,070)
Adjustments to reconcile net loss to net cash used in operating activities:        
Depreciation and amortization    
Stock based compensation     356,032 100,000
Interest expense     97,988
Increase in current assets        
Prepaid expenses     (109,356) (12,500)
Subscription Receivable    
Increase in current assets     (109,356) (12,500)
Increase in current liabilities        
Accounts payable and accrued liabilities     247,846 50,038
Short-term loans from shareholders (net)     906,196 332,668
Increase in current liabilities     1,154,042 382,706
Net cash flows used in operating activities     (265,186) 11,136
Cash Flows from Investing Activities:        
Net cash provided by (used in) investing activities    
CASH FLOWS FROM FINANCING ACTIVITIES        
Series A Preferred stock, par value $0.0001     32
Additional paid in capital     257,613
Net cash flows provided by financing activities     257,645
NET CHANGE IN CASH     (7,541) 11,136
CASH, BEGINNING OF THE PERIOD 3,633 11,174 11,174 38
CASH, END OF THE PERIOD     3,633 11,174
Supplemental disclosure of cash flow information:        
Cash paid for interest    
Cash paid for income taxes     1,013
Note Payable addition from OID     280,549
Parent Company [Member]        
CASH FLOWS FROM OPERATING ACTIVITIES        
Net loss (17,922,621) (327,893)    
Adjustments to reconcile net loss to net cash used in operating activities:        
Change in fair value of derivative liabilities 384,318    
Loss on extinguishment of debt 364,109    
Stock based compensation 14,131,250    
Interest expense 817,824    
Increase in current assets        
Prepaid expenses (553,833) 5,000    
Increase in current liabilities        
Accounts payable 1,041,420 (11,244)    
Accrued expenses (15,359)    
Other current liabilities (111,026) 150    
Due from related party (1,027,920) 84,772    
Net cash flows used in operating activities (2,891,838) (249,215)    
CASH FLOWS FROM FINANCING ACTIVITIES        
Repayment of notes payable – related party (221,390)    
Proceeds from issuance of convertible notes 3,000,000    
Proceeds from notes payable - related party 50,000    
Issuance of common stock 257,645    
Proceeds from Recapitalization 265,828    
Net cash flows provided by financing activities 3,094,438 257,645    
NET CHANGE IN CASH 202,600 8,430    
CASH, BEGINNING OF THE PERIOD 3,633 11,174 11,174  
CASH, END OF THE PERIOD 206,233 19,604 $ 3,633 $ 11,174
Supplemental disclosure of cash flow information:        
Accounts payable, accrued liabilities and other current liabilities combined 1,577,057    
Promissory Note fee – related party combined 1,000,000    
Subscription agreement loans combined 1,828,098    
Loan and transfer note payable combined 499,214    
Forward purchase agreement liability combined 49,034    
Issuance of Class A ordinary shares for services $ 14,448,500